explore -WSS

explore

author：Wikipedia 2025-09-30 08:52:31 - browse：652

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Readout LOUD podcast: What to know about H5N1 bird flu

leisure time

WSS

Elevance, private equity launch primary care company

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Google says AlphaFold 3 can map a vast universe of biomolecules

How a scoliosis diagnosis changed the life of one young dancer

Chronically ill young patients struggle to find fertility info

Study: Adult vaccinations pay for themselves in societal benefits

hotspot

explore

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Making AI in medicine accessible to smaller, and rural hospitals

Drug repurposing or repositioning? The language matters

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Medical leaders decry Supreme Court decision on affirmative action

Dairy farmers resist CDC push for PPE against bird flu virus

United colonoscopy coverage change 'may cost lives,' doctors say

Shionogi licenses Pompe disease therapy from Maze Therapeutics

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: What to know about H5N1 bird flu

Wikipedia

White House finalizes ITC's import ban of latest Apple Watches

3 medical device trends to watch in 2024

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

How to improve immunocompromised access to mAb treatments

Videos point to link between seizures and unexplained toddler deaths

JPM: CVS says Medicare Advantage patients are impacting profits

Wikipedia

leisure time

focus

focus